… development to reduce the residual risk on statin therapy linked … update on the biology,
epidemiology and genetics of triglycerides, and the risk of atherosclerotic cardiovascular disease…

… Atherosclerotic cardiovascular disease (ASCVD) is caused by elevated levels of low-density …
The purpose of this review is to provide an update on recent evidence supporting the use of …

… The study found that the increase in Lp(a) can independently predict long-term atherosclerotic
cardiovascular disease (ASCVD) and CHD risks in asymptomatic populations of the …

Dyslipidemia is a potent risk factor for the genesis and progression of cardiovascular disease
(CVD), and both the concentration and type of low-density lipoproteins (LDL) augment this …

… caused by atherosclerotic cardiovascular disease (ASCVD) … , the latest American Heart
Disease and Stroke Statistics show … , and HDL cholesterol. The association of on-statin Lp(a) with …

… The purpose of this review is to discuss the updated guideline recommendations on
management of dyslipidemia for prevention and treatment of cardiovascular disease. …

… Higher cholesterol efflux capacity of plasma HDL, … lower risk of incident coronary heart
disease events. The correlation between plasma HDL cholesterol mass efflux capacity and HDL-C …

… For primary analyses, lipid measurements and these concordance groups were considered
as time-dependent covariates and updated at each ARIC study visit making our analyses …

… One MR study from 2016 used the most updated publicly available genetic consortia data
available at that timepoint and applied sensitivity analyses, addressing pleiotropy and weak …

… The 2018 American Heart Association (AHA)/American College of Cardiology (ACC) … clinical
atherosclerotic cardiovascular disease (ASCVD) into high-risk and very high-risk categories…